The observed treatment advantages were primarily attributed to the ulcerative colitis (UC) subgroup, wherein familial patients demonstrated significantly elevated rates of mucosal healing, clinical response, remission, and CRP normalization (all p < 0.05, Table 6; Fig. 5). The gene discussed is CRP; the disease is ulcerative colitis.